Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Deletion at 6q24.2-26 predicts longer survival of high-grade serous epithelial ovarian cancer patients., Deletion at 6q24.2–26 predicts longer survival of high-grade serous epithelial ovarian cancer patients

  • Kamieniak, Marta M.
  • Rico, Daniel
  • Milne, Roger L.
  • Muñoz-Repeto, Ivan
  • Ibáñez, Kristina
  • Grillo, Miguel A.
  • Domingo, Samuel
  • Borrego, Salud
  • Cazorla, Alicia
  • García-Bueno, José M.
  • Hernando, Susana
  • García-Donas, Jesús
  • Hernández-Agudo, Elena
  • Y Cajal, Teresa Ramón
  • Robles-Díaz, Luis
  • Márquez-Rodas, Ivan
  • Cusidó, Maite
  • Sáez, Raquel
  • Lacambra-Calvet, Carmen
  • Osorio, Ana
  • Urioste, Miguel
  • Cigudosa, Juan C.
  • Paz-Ares, Luis
  • Palacios Calvo, José
  • Benítez, Javier
  • García, María J.
Standard treatments for advanced high-grade serous ovarian carcinomas (HGSOCs) show significant side-effects and provide only short-term survival benefits due to disease recurrence. Thus, identification of novel prognostic and predictive biomarkers is urgently needed. We have used 42 paraffin-embedded HGSOCs, to evaluate the utility of DNA copy number alterations, as potential predictors of clinical outcome. Copy number-based unsupervised clustering stratified HGSOCs into two clusters of different immunohistopathological features and survival outcome (HR = 0.15, 95%CI = 0.03–0.81; Padj = 0.03). We found that loss at 6q24.2–26 was significantly associated with the cluster of longer survival independently from other confounding factors (HR = 0.06, 95%CI = 0.01–0.43, Padj = 0.005). The prognostic value of this deletion was validated in two independent series, one consisting of 36 HGSOCs analyzed by fluorescent in situ hybridization (P = 0.04) and another comprised of 411 HGSOCs from the Cancer Genome Atlas study (TCGA) (HR = 0.67, 95%CI = 0.48–0.93, Padj = 0.019). In addition, we confirmed the association of low expression of the genes from the region with longer survival in 799 HGSOCs (HR = 0.74, 95%CI = 0.61–0.90, log-rank P = 0.002) and 675 high-FIGO stage HGSOCs (HR = 0.76, 95%CI = 0.61–0.96, log-rank P = 0.02) available from the online tool KM-plotter. Finally, by integrating copy number, RNAseq and survival data of 296 HGSOCs from TCGA we propose a few candidate genes that can potentially explain the association. Altogether our findings indicate that the 6q24.2–26 deletion is an independent marker of favorable outcome in HGSOCs with potential clinical value as it can be analyzed by FISH on tumor sections and guide the selection of patients towards more conservative therapeutic strategies in order to reduce side-effects and improve quality of life., This study was financially supported by the Fondo de Investigación Sanitaria (FIS), Instituto de Salud Carlos III (grants PS09/01094 and PI12/01319). MJG is recipient of a research contract from the Instituto de Salud Carlos III of the Ministerio Español de Sanidad y Consumo (Miguel Servet tipo II Program, CPII 13/00047). MMK and KI have financial support from the Fundación La Caixa. DR and KI are supported by grant BIO2012-40205. LP-A, JCC and JP are recipients of financial support from Red Temática de Investigación Cooperativa en Cáncer (RTICC) (grants RD12/0036/0028, RD12/0036/0037 and RD12/0036/0064)., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer

  • Hergueta-Redondo, Marta
  • Sarrio, David
  • Molina-Crespo, Ángela
  • Vicario, Rocío
  • Bernadó Morales, Cristina|||0000-0003-1376-0407
  • Martínez, Lidia
  • Rojo-Sebastián, Alejandro
  • Serra-Musach, Jordi
  • Mota, Alba
  • Martínez-Ramírez, Ángel
  • Castilla, Maria Ángeles
  • González-Martin, Antonio
  • Pernas, Sonia|||0000-0002-1485-5080
  • Cano, Amparo
  • Cortés Castán, Javier|||0000-0001-7623-1583
  • Nuciforo, Paolo|||0000-0003-1380-0990
  • Peg, Vicente|||0000-0002-5203-6166
  • Palacios, José|||0000-0002-6730-5066
  • Pujana, Miguel Angel|||0000-0003-3222-4044
  • Arribas, Joaquín V.|||0000-0002-0504-0664
  • Moreno-Bueno, Gema
Around, 30-40% of HER2-positive breast cancers do not show substantial clinical benefit from the targeted therapy and, thus, the mechanisms underlying resistance remain partially unknown. Interestingly, ERBB2 is frequently co-amplified and co-expressed with neighbour genes that may play a relevant role in this cancer subtype. Here, using an in silico analysis of data from 2,096 breast tumours, we reveal a significant correlation between Gasdermin B (GSDMB) gene (located 175 kilo bases distal from ERBB2) expression and the pathological and clinical parameters of poor prognosis in HER2-positive breast cancer. Next, the analysis of three independent cohorts (totalizing 286 tumours) showed that approximately 65% of the HER2-positive cases have GSDMB gene amplification and protein over-expression. Moreover, GSDMB expression was also linked to poor therapeutic responses in terms of lower relapse free survival and pathologic complete response as well as positive lymph node status and the development of distant metastasis under neoadjuvant and adjuvant treatment settings, respectively. Importantly, GSDMB expression promotes survival to trastuzumab in different HER2-positive breast carcinoma cells, and is associated with trastuzumab resistance phenotype in vivo in Patient Derived Xenografts. In summary, our data identifies the ERBB2 co-amplified and co-expressed gene GSDMB as a critical determinant of poor prognosis and therapeutic response in HER2-positive breast cancer.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Deletion at 6q24.2-26 predicts longer survival of high-grade serous epithelial ovarian cancer patients

  • Kamieniak, Marta M.
  • Rico, Daniel|||0000-0002-6561-2310
  • Milne, Roger L.|||0000-0001-5764-7268
  • Muñoz-Repeto, Ivan
  • Ibáñez, Kristina
  • Grillo, Miguel A.
  • Domingo, Samuel
  • Borrego, Salud|||0000-0002-2513-6161
  • Cazorla-Jiménez, Alicia|||0000-0002-9534-8418
  • García-Bueno, José María|||0000-0003-3892-8894
  • Hernando, Susana
  • García Donas, J.|||0000-0001-7731-3601
  • Hernández-Agudo, Elena
  • Ramon y Cajal, Teresa|||0000-0003-3490-3585
  • Robles-Díaz, Luis|||0000-0002-8909-8520
  • Márquez Rodas, Ivan|||0000-0002-2476-668X
  • Cusidó, Maite|||0000-0003-1631-1500
  • Sáez, Raquel
  • Lacambra, Carmen
  • Osorio, Ana|||0000-0001-8124-3984
  • Urioste, Miguel|||0000-0001-7583-7305
  • Cigudosa, Juan C.
  • Paz-Ares, Luis|||0000-0002-3327-3246
  • Palacios, José|||0000-0002-6730-5066
  • Benitez, Javier|||0000-0002-0923-7202
  • García, María J.
Standard treatments for advanced high-grade serous ovarian carcinomas (HGSOCs) show significant side-effects and provide only short-term survival benefits due to disease recurrence. Thus, identification of novel prognostic and predictive biomarkers is urgently needed. We have used 42 paraffin-embedded HGSOCs, to evaluate the utility of DNA copy number alterations, as potential predictors of clinical outcome. Copy number-based unsupervised clustering stratified HGSOCs into two clusters of different immunohistopathological features and survival outcome (HR=0.15, 95%CI=0.03-0.81; P=0.03). We found that loss at 6q24.2-26 was significantly associated with the cluster of longer survival independently from other confounding factors (HR=0.06, 95%CI=0.01-0.43, P=0.005). The prognostic value of this deletion was validated in two independent series, one consisting of 36 HGSOCs analyzed by fluorescent in situ hybridization (P=0.04) and another comprised of 411 HGSOCs from the Cancer Genome Atlas study (TCGA) (HR=0.67, 95%CI=0.48-0.93, P=0.019). In addition, we confirmed the association of low expression of the genes from the region with longer survival in 799 HGSOCs (HR=0.74, 95%CI=0.61-0.90, log-rank P=0.002) and 675 high-FIGO stage HGSOCs (HR=0.76, 95%CI=0.61-0.96, log-rank P=0.02) available from the online tool KM-plotter. Finally, by integrating copy number, RNAseq and survival data of 296 HGSOCs from TCGA we propose a few candidate genes that can potentially explain the association. Altogether our findings indicate that the 6q24.2-26 deletion is an independent marker of favorable outcome in HGSOCs with potential clinical value as it can be analyzed by FISH on tumor sections and guide the selection of patients towards more conservative therapeutic strategies in order to reduce side-effects and improve quality of life.